IART
Integra Lifesciences Holdings·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IART
Integra Lifesciences Holdings Corporation
A global leader in regenerative tissue technologies and neurosurgical solutions
Healthcare Equipment and Supplies
--
08/16/1995
NASDAQ Stock Exchange
4,396
12-31
Common stock
1100 Campus Road, Princeton, New Jersey 08540
--
Integra Lifesciences Holdings Corporation, incorporated in Delaware in 1989, is a leading global medical technology company that improves patient prognosis through innovative therapeutic pathways and sets new standards for surgical, neurological and regenerative care. Through global acquisitions and product development, the company has expanded its base regenerative technology business to include surgical instruments, neurosurgery products and advanced wound care to meet the changing needs of customers and enhance patient care.
Company Financials
EPS
IART has released its 2025 Q3 earnings. EPS was reported at 0.54, versus the expected 0.43, beating expectations. The chart below visualizes how IART has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IART has released its 2025 Q3 earnings report, with revenue of 402.06M, reflecting a YoY change of 5.57%, and net profit of -5.40M, showing a YoY change of 49.47%. The Sankey diagram below clearly presents IART's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
